Leukemia Research
Volume 26, Issue 8 , Pages 703-704 , August 2002

Commentary: targeting myelodysplastic syndromes

Received 21 January 2002 ,Accepted 21 January 2002.

References 

  1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 2001;344:1031–1042
  2. Mauro MJ, O’Dwyer ME, Druker BJ. Development of STI571 and its use in chronic myelogenous leukemia and other malignancies. Oncol. Spectr. 2001;8:536–541
  3. Rosenfeld CS, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndromes. Leuk Research 2002;26:721–4,

    PII: S0145-2126(01)00201-6.

  4. Hellstrom-Lindberg E. Treatment of adult myelodysplastic syndromes. Int. J. Hematol. 1999;70:141–154
  5. Parker JE, Mufti GJ. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk. Lymphoma. 2000;40:1–24
  6. Yoshida Y, Mufti GJ. Apoptosis and its significance in MDS: controversies revisited. Leuk. Res. 1999;23:777–785
  7. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al.  Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int. J. Hematol. 1996;63:265–278
  8. Verhoef GEG, DeSchouwer P, Ceuppens JL, VanDamme J, Goosens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992;12:1268–1272
  9. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al.  A role for tumour necrosis factor-α, Fas, and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br. J. Haematol. 1998;103:176–188
  10. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk. Res. 1995;19:639–644
  11. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, et al.  Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049–2054
  12. Stasi R, Bruneti M, Bussa S, Conforti M, Martin LS, Presa ML, et al.  Serum levels of tumor necrosis factor-α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin. Lab. Haematol. 1997;19:197–201
  13. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, et al.  Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk. Res. 1996;20:891–900
  14. Cully CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential application in myelodysplastic syndrome. Drugs. 2001;61:641–684
  15. Raza A, Allampallam K, Shetty V, Mundle S, Borok R, Lisak L, et al. Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (Enbrel) in patients with myelodysplastic syndromes (MDS). Blood (abstract) 1999; 94(Suppl 1, pt 2):171b.
  16. Deeg HJ, Gotlib J, Beckman C, Dugan F, Applebaum F, Greenberg P. Soluble TNF receptor fusion protein (TNFR:Fc; Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS). Blood (abstract) 2000; 96(11):146a.
  17. Maciejewski JP, Wisch L, Barrett AJ, Young NS. Pathophsyiologic role of Tumor Necrosis Factor-α in myelodysplastic syndrome (MDS)—effects of anti-TNF therapy with soluble TNF receptor-Fc fusion protein (Enbrel). Leuk Res (abstract) 2001; 25(Suppl 1):P102.
  18. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 2000;50:229–235

PII: S0145-2126(02)00024-3

Leukemia Research
Volume 26, Issue 8 , Pages 703-704 , August 2002

Article Tools